Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study

Leuk Lymphoma. 2022 Nov;63(11):2760-2761. doi: 10.1080/10428194.2022.2095626. Epub 2022 Jul 15.

Sham Mailankody^{1

2}, Meghan Salcedo¹, Elizabet Tavitian³, Miranda Burge¹, Neha Korde^{1

2}, Hani Hassoun^{1

2}, Alexander Lesokhin^{1

2}, Oscar Lahoud^{2

4}, Eric Smith⁵, Malin Hultcrantz^{1

2}, Carlyn Tan^{1

2}, Urvi Shah^{1

2}, Sean Devlin⁶, Ola Landgren^{1

7}

¹ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
³ PRA Health Sciences, Raleigh, NC, USA.
⁴ BMT service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁶ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Myeloma Program and Experimental Therapeutics Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.

No abstract available

Publication types